Non-target genetic manipulation induces rhabdomyosarcoma in KrasPten-driven mouse model of ovarian cancer

Lai, Hui‐Ling; Guo, Yunyun; He, Weipeng; Sun, Tingting; Ouyang, Linglong; Tian, Liming; Li, Yuanyuan; Li, Xiaohui; Zhang, You; Yang, Guimei

doi:10.21037/tcr-20-2561

Cited by 2 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Orthotopic CDX models and GEMM which scored highly accounted for 24.6% (n = 29). Two GEMM models were downclassified to the 'low' category, with one study reporting the accidental development of RMS in an ovarian cancer mouse model due to non-specific genetic manipulation (19), and the other study reporting IGF-2 overexpressing pelvic RMS with concomitant salivary carcinoma (20). Ectopic or orthotopic PDX models accounted for 15.3% (n = 18) of trials.…”

Section: Resultsmentioning

confidence: 99%

“…Moreover, ectopic mouse models did not recapitulate any of the human anatomical tumor sites, thus having very limited translational value. While orthotopic mouse models recapitulated the limb RMS phenotype, a variety of additional tumor locations were observed merely in GEMM systems within our study cohort, including the abdomen, back, head/neck, rib cage, pelvis, body wall, and tongue (19,20,27,(64)(65)(66)(67)(68)(69)(70).…”

Section: From Bedside To Benchmentioning

confidence: 88%

See 1 more Smart Citation

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside

Martynov,

Dhaka,

Wilke

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundRhabdomyosarcoma (RMS) is the most common pediatric soft-tissue malignancy, characterized by high clinicalopathological and molecular heterogeneity. Preclinical in vivo models are essential for advancing our understanding of RMS oncobiology and developing novel treatment strategies. However, the diversity of scholarly data on preclinical RMS studies may challenge scientists and clinicians. Hence, we performed a systematic literature survey of contemporary RMS mouse models to characterize their phenotypes and assess their translational relevance.MethodsWe identified papers published between 01/07/2018 and 01/07/2023 by searching PubMed and Web of Science databases.ResultsOut of 713 records screened, 118 studies (26.9%) were included in the qualitative synthesis. Cell line-derived xenografts (CDX) were the most commonly utilized (n = 75, 63.6%), followed by patient-derived xenografts (PDX) and syngeneic models, each accounting for 11.9% (n = 14), and genetically engineered mouse models (GEMM) (n = 7, 5.9%). Combinations of different model categories were reported in 5.9% (n = 7) of studies. One study employed a virus-induced RMS model. Overall, 40.0% (n = 30) of the studies utilizing CDX models established alveolar RMS (aRMS), while 38.7% (n = 29) were embryonal phenotypes (eRMS). There were 20.0% (n = 15) of studies that involved a combination of both aRMS and eRMS subtypes. In one study (1.3%), the RMS phenotype was spindle cell/sclerosing. Subcutaneous xenografts (n = 66, 55.9%) were more frequently used compared to orthotopic models (n = 29, 24.6%). Notably, none of the employed cell lines were derived from primary untreated tumors. Only a minority of studies investigated disseminated RMS phenotypes (n = 16, 13.6%). The utilization areas of RMS models included testing drugs (n = 64, 54.2%), studying tumorigenesis (n = 56, 47.5%), tumor modeling (n = 19, 16.1%), imaging (n = 9, 7.6%), radiotherapy (n = 6, 5.1%), long-term effects related to radiotherapy (n = 3, 2.5%), and investigating biomarkers (n = 1, 0.8%). Notably, no preclinical studies focused on surgery.ConclusionsThis up-to-date review highlights the need for mouse models with dissemination phenotypes and cell lines from primary untreated tumors. Furthermore, efforts should be directed towards underexplored areas such as surgery, radiotherapy, and biomarkers.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: From Bedside To Benchmentioning

confidence: 88%

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside

Martynov,

Dhaka,

Wilke

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Embryonal rhabdomyosarcoma (ERMS) is a rare category of soft tissue sarcoma (STS) that originates in the mesenchymal tissue. There are three major histologic subtypes of rhabdomyosarcoma (1,2) and the head and neck region represent the most affected site. Surgery is the best method for removing early-stage tumors (3); however, a high risk of recurrence or distant metastasis remains afterward.…”

Section: Introductionmentioning

confidence: 99%

Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report

Xing

Zhang

et al. 2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

Embryonal rhabdomyosarcoma (ERMS) is associated with a low prevalence, poor prognosis, and limited treatment efficacy. Here, we report a case of a 21-year-old male whose disease relapsed in the thoracic cavity following traditional chemotherapy. The patient received eight sequential cycles of traditional chemotherapy using a combination of the cyclophosphamid + vincristine + doxorubicin hydrochloride liposome (CAV) and etoposide + ifosfamide (IE) regimens. The therapeutic effect of the combination regimen had been worked in short times. After a month, ERMS had relapsed in the whole lung after traditional chemotherapy. The treatment method was changed immediately and the patient received targeted therapy with a combination of pazopanib and olaratumab. The therapeutic effect of the combination regimen was evaluated for a complete response (CR). After two months, CT imaging revealed that most of the metastatic lesions in the lung had disappeared. This is the first case to report the use of pazopanib and olaratumab in relapsed ERMS with a curative effect resulting in a CR. Pazopanib is approved for advanced soft tissue sarcoma (STS) and renal cell cancer. Thus, combining pazopanib with targeted therapy may play an important role and provide a reference for the treatment of relapsed ERMS.

show abstract

Non-target genetic manipulation induces rhabdomyosarcoma in KrasPten-driven mouse model of ovarian cancer

Cited by 2 publications

References 39 publications

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside

Contemporary preclinical mouse models for pediatric rhabdomyosarcoma: from bedside to bench to bedside

Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report

Contact Info

Product

Resources

About